The first patient has
been implanted with the Boston Scientific Corporation BSX next
generation INGEVITY™ pacing leads in a clinical trial designed to establish
the safety, performance and effectiveness of the leads. Pacing leads are
insulated wires that connect an implantable pacemaker to the heart for
treatment of bradycardia, a condition in which the heart beats too slowly,
depriving the body of sufficient oxygen. Pacemakers work in conjunction with
leads to sense and stimulate (or pace) the heart, thus maintaining an
appropriate heart rate for a given level of physical activity.
The INGEVITY pacing lead platform is designed to provide key enhancements in
maneuverability, reliability, fixation and electrical performance compared to
standard leads available today. In addition, INGEVITY leads are specifically
engineered to function in the magnetic resonance imaging (MRI) environment.
Many patients with pacemakers are restricted from undergoing MRI scans, as
powerful magnets may interfere with pacemaker functionality.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in